Does the media favor SLGL or ATYR?

In the previous week, Sol-Gel Technologies had 10 more articles in the media than aTyr Pharma. MarketBeat recorded 12 mentions for Sol-Gel Technologies and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 1.60 beat Sol-Gel Technologies' score of -0.26 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer KPTI or ATYR?

In the previous week, Karyopharm Therapeutics had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 6 mentions for Karyopharm Therapeutics and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 1.60 beat Karyopharm Therapeutics' score of 0.32 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, IMUX or ATYR?

aTyr Pharma has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A aTyr Pharma $190K 277.12 -$74.12M -$0.73 N/A

Is IMUX or ATYR more profitable?

aTyr Pharma's return on equity of -100.14% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% aTyr Pharma N/A -100.14% -73.55%

Which has higher valuation & earnings, ATYR or IMDX?

Oncocyte has higher revenue and earnings than aTyr Pharma. Oncocyte is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 277.12 -$74.12M -$0.73 N/A Oncocyte $4.05M 52.54 -$50.22M -$1.48 N/A

Is ATYR or IMDX more profitable?

aTyr Pharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Oncocyte -2,454.64% N/A -96.96%

Do analysts prefer ATYR or INDP?

aTyr Pharma currently has a consensus target price of $21.00, suggesting a potential upside of 3,810.61%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATYR or INDP more profitable?

aTyr Pharma's return on equity of -100.14% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Indaptus Therapeutics N/A -1,030.07% -299.69%

Does the media favor ATYR or INDP?

In the previous week, aTyr Pharma had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for Indaptus Therapeutics. aTyr Pharma's average media sentiment score of 1.60 beat Indaptus Therapeutics' score of 0.93 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Indaptus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

aTyr Pharma (ATYR) Competitors

$0.54 +0.04 (+7.38%)

As of 12:44 PM Eastern

Compare

ATYR vs. SLGL, KPTI, IMUX, IMDX, and INDP

Should you buy aTyr Pharma stock or one of its competitors? MarketBeat compares aTyr Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with aTyr Pharma include Sol-Gel Technologies (SLGL), Karyopharm Therapeutics (KPTI), Immunic (IMUX), Oncocyte (IMDX), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry.

How does aTyr Pharma compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sol-Gel Technologies has higher revenue and earnings than aTyr Pharma. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.57	-$6.13M	-$0.34	N/A
aTyr Pharma	$190K	277.12	-$74.12M	-$0.73	N/A

In the previous week, Sol-Gel Technologies had 10 more articles in the media than aTyr Pharma. MarketBeat recorded 12 mentions for Sol-Gel Technologies and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 1.60 beat Sol-Gel Technologies' score of -0.26 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

aTyr Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
aTyr Pharma	N/A	-100.14%	-73.55%

Sol-Gel Technologies presently has a consensus target price of $110.00, indicating a potential upside of 50.80%. aTyr Pharma has a consensus target price of $21.00, indicating a potential upside of 3,810.61%. Given aTyr Pharma's higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Sol-Gel Technologies has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

Sol-Gel Technologies beats aTyr Pharma on 10 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Karyopharm Therapeutics had 4 more articles in the media than aTyr Pharma. MarketBeat recorded 6 mentions for Karyopharm Therapeutics and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 1.60 beat Karyopharm Therapeutics' score of 0.32 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Karyopharm Therapeutics currently has a consensus target price of $17.17, suggesting a potential upside of 91.46%. aTyr Pharma has a consensus target price of $21.00, suggesting a potential upside of 3,810.61%. Given aTyr Pharma's higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

aTyr Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
aTyr Pharma	N/A	-100.14%	-73.55%

Karyopharm Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

aTyr Pharma has lower revenue, but higher earnings than Karyopharm Therapeutics. aTyr Pharma is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.39	-$196.04M	-$15.09	N/A
aTyr Pharma	$190K	277.12	-$74.12M	-$0.73	N/A

Summary

Karyopharm Therapeutics and aTyr Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Immunic?

Immunic (NASDAQ:IMUX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

51.8% of Immunic shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 14.0% of Immunic shares are held by insiders. Comparatively, 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

aTyr Pharma's return on equity of -100.14% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
aTyr Pharma	N/A	-100.14%	-73.55%

aTyr Pharma has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
aTyr Pharma	$190K	277.12	-$74.12M	-$0.73	N/A

Immunic presently has a consensus price target of $47.57, indicating a potential upside of 225.72%. aTyr Pharma has a consensus price target of $21.00, indicating a potential upside of 3,810.61%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, aTyr Pharma had 2 more articles in the media than Immunic. MarketBeat recorded 2 mentions for aTyr Pharma and 0 mentions for Immunic. aTyr Pharma's average media sentiment score of 1.60 beat Immunic's score of 0.73 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunic	Positive
aTyr Pharma	Very Positive

Summary

aTyr Pharma beats Immunic on 10 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Oncocyte?

aTyr Pharma (NASDAQ:ATYR) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Oncocyte has higher revenue and earnings than aTyr Pharma. Oncocyte is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	277.12	-$74.12M	-$0.73	N/A
Oncocyte	$4.05M	52.54	-$50.22M	-$1.48	N/A

aTyr Pharma currently has a consensus price target of $21.00, indicating a potential upside of 3,810.61%. Oncocyte has a consensus price target of $12.00, indicating a potential upside of 82.09%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, aTyr Pharma had 2 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for aTyr Pharma and 0 mentions for Oncocyte. aTyr Pharma's average media sentiment score of 1.60 beat Oncocyte's score of 0.44 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Very Positive
Oncocyte	Neutral

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 2.1% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

aTyr Pharma has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Oncocyte	-2,454.64%	N/A	-96.96%

aTyr Pharma has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Summary

aTyr Pharma beats Oncocyte on 12 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Indaptus Therapeutics?

aTyr Pharma (NASDAQ:ATYR) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

aTyr Pharma currently has a consensus target price of $21.00, suggesting a potential upside of 3,810.61%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts clearly believe aTyr Pharma is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	277.12	-$74.12M	-$0.73	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

In the previous week, aTyr Pharma had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for aTyr Pharma and 1 mentions for Indaptus Therapeutics. aTyr Pharma's average media sentiment score of 1.60 beat Indaptus Therapeutics' score of 0.93 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Indaptus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

aTyr Pharma has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

aTyr Pharma's return on equity of -100.14% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Summary

aTyr Pharma beats Indaptus Therapeutics on 11 of the 15 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.65M	$3.35B	$6.45B	$12.42B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.74	18.82	23.89	24.35
Price / Sales	277.12	322.47	524.38	119.30
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.78	6.85	10.06	6.74
Net Income	-$74.12M	$24.15M	$3.56B	$337.03M
7 Day Performance	10.18%	-1.87%	-0.60%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.60%
1 Year Performance	-89.55%	49.61%	29.29%	34.04%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	3.4266 of 5 stars	$0.54 +7.4%	$25.67 +4,679.6%	-90.7%	$52.65M	$190K	N/A	53	Positive News
SLGL Sol-Gel Technologies	3.6762 of 5 stars	$70.40 -4.7%	$110.00 +56.3%	+872.7%	$207.54M	$18.47M	N/A	50	News Coverage Earnings Report Short Interest Decrease Analyst Revision
KPTI Karyopharm Therapeutics	2.7468 of 5 stars	$9.82 +7.9%	$17.17 +74.8%	+111.8%	$206.23M	$151.12M	N/A	380
IMUX Immunic	2.9472 of 5 stars	$15.13 +1.1%	$47.57 +214.4%	+94.0%	$203.79M	N/A	N/A	70
IMDX Oncocyte	2.6932 of 5 stars	$6.16 -0.8%	$12.00 +94.8%	N/A	$200.52M	$4.05M	N/A	120	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors

ATYR vs. SLGL, KPTI, IMUX, IMDX, and INDP

How does aTyr Pharma compare to Sol-Gel Technologies?

Summary

How does aTyr Pharma compare to Karyopharm Therapeutics?

Summary

How does aTyr Pharma compare to Immunic?

Summary

How does aTyr Pharma compare to Oncocyte?

Summary

How does aTyr Pharma compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

aTyr Pharma (ATYR) Competitors

ATYR vs. SLGL, KPTI, IMUX, IMDX, and INDP

How does aTyr Pharma compare to Sol-Gel Technologies?

Do institutionals and insiders have more ownership in SLGL or ATYR?

Which has stronger earnings and valuation, SLGL or ATYR?

Does the media favor SLGL or ATYR?

Is SLGL or ATYR more profitable?

Do analysts rate SLGL or ATYR?

Which has more risk & volatility, SLGL or ATYR?

Summary

How does aTyr Pharma compare to Karyopharm Therapeutics?

Does the media prefer KPTI or ATYR?

Do analysts recommend KPTI or ATYR?

Is KPTI or ATYR more profitable?

Which has more volatility & risk, KPTI or ATYR?

Do institutionals & insiders have more ownership in KPTI or ATYR?

Which has higher valuation and earnings, KPTI or ATYR?

Summary

How does aTyr Pharma compare to Immunic?

Do institutionals and insiders believe in IMUX or ATYR?

Which has more risk & volatility, IMUX or ATYR?

Is IMUX or ATYR more profitable?

Which has better valuation and earnings, IMUX or ATYR?

Do analysts rate IMUX or ATYR?

Does the media prefer IMUX or ATYR?

Summary

How does aTyr Pharma compare to Oncocyte?

Which has higher valuation & earnings, ATYR or IMDX?

Do analysts recommend ATYR or IMDX?

Does the media favor ATYR or IMDX?

Do insiders & institutionals believe in ATYR or IMDX?

Is ATYR or IMDX more profitable?

Which has more volatility and risk, ATYR or IMDX?

Summary

How does aTyr Pharma compare to Indaptus Therapeutics?

Do analysts prefer ATYR or INDP?

Which has preferable earnings and valuation, ATYR or INDP?

Does the media favor ATYR or INDP?

Which has more volatility and risk, ATYR or INDP?

Do institutionals & insiders have more ownership in ATYR or INDP?

Is ATYR or INDP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR vs. The Competition

aTyr Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools